Imatinib Quantification in rat plasma by high performance liquid chromatography with ultra violet detection - An application to Preclinical Pharmacokinetic study.

Summary A simple and robust method for quantification of imatinib in rat plasma has been established using high performance liquid chromatography with UV detection. Mizolastine was used as an internal standard (IS). imatinib and internal standard in plasma sample were extracted using simple protein precipitation technique. The samples were injected into a C18 reverse-phase phenyl column and mobile phase used was acetonitrile – phosphate buffer (pH3.2; 25.0 mM) (24:76%, v/v) at a flow rate of 1.0 mL min -1 using ultraviolet detector. imatinib and internal standard were detected without any interference from rat plasma. Detection of imatinib in rat plasma by the high performance liquid chromatography method was accurate and precise with a quantitation limit of 20.0 ng mL -1 . The proposed method was validated with linearity range of 20.0 – 10000.0 ng mL -1 . Reproducibility, recovery and stability of the method were evaluated. This method has been successfully applied to pharmacokinetic evaluation of imatinib liposome formulation.

[1]  J. Biollaz,et al.  Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. , 2008, Journal of mass spectrometry : JMS.

[2]  F. Lee,et al.  Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor , 2008, Cancer Chemotherapy and Pharmacology.

[3]  J. Schellens,et al.  Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. , 2007, Biomedical chromatography : BMC.

[4]  Gunther Guetens,et al.  Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry. , 2006, Journal of separation science.

[5]  P. Berthaud,et al.  Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry , 2005, Therapeutic drug monitoring.

[6]  J. J. Berzas Nevado,et al.  Nonaqueous capillary electrophoresis method for the analysis of gleevec and its main metabolite in human urine. , 2005, Journal of chromatography. A.

[7]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[8]  M. Ogura,et al.  Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study , 2004, International journal of hematology.

[9]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Gupta,et al.  Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  T. Buclin,et al.  Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  F. Balis,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates , 2004, Clinical Cancer Research.

[13]  M. Highley,et al.  Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. A.

[14]  G. Castañeda,et al.  Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  M. Egorin,et al.  Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  F. Tse,et al.  Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. , 2002, Journal of pharmaceutical and biomedical analysis.

[17]  B. Druker,et al.  STI571 (Gleevec) as a paradigm for cancer therapy. , 2002, Trends in molecular medicine.

[18]  F. Tse,et al.  High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  S. Primack,et al.  Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. , 2004, Haematologica.

[20]  M. Hearn [9] Reversed-phase high-performance liquid chromatography , 1984 .